Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 10/20 | 0.64 |
| ▸ | AR | P10275 | 9/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.64 |
| ▸ | HTR2B | P41595 | 2/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | SHBG | P04278 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.53 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.53 |
| ▸ | BLM | P54132 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.53 |
| ▸ | SNCA | P37840 | 2/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14256416 | 1.00 | PGR (0.64) | PGRARLMNANR3C1HTR2B | |
| SCHEMBL11041227 | 1.00 | PGR (0.64) | PGRARLMNANR3C1HTR2B | |
| SCHEMBL14256378 | 1.00 | PGR (0.64) | PGRARLMNANR3C1HTR2B | |
| SCHEMBL10939751 | 0.93 | SHBG (0.56) | PGRARLMNANR3C1HTR2B | |
| SCHEMBL18220867 | 0.86 | SHBG (0.54) | PGRARLMNANR3C1HTR2B | |
| SCHEMBL13936414 | 0.84 | CYP19A1 (0.54) | PGRARLMNANR3C1HTR2B | |
| SCHEMBL13103488 | 0.84 | PGR (0.72) | PGRARLMNANR3C1HTR2B | |
| SCHEMBL14668726 | 0.84 | PGR (0.72) | PGRARLMNANR3C1HTR2B | |
| SCHEMBL12568120 | 0.83 | PGR (0.65) | PGRARLMNANR3C1HTR2B | |
| SCHEMBL16852314 | 0.83 | PGR (0.65) | PGRARLMNANR3C1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324874-A1 | RETINOID X RECEPTOR-GAMMA AGONISTS AND RETINOID X RECEPTOR-ALPHA ANTAGONISTS FOR TREATMENT OF CANCER | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324874-A1 | RETINOID X RECEPTOR-GAMMA AGONISTS AND RETINOID X RECEPTOR-ALPHA ANTAGONISTS FOR TREATMENT OF CANCER | RXRG, RXRA, RXRB | PGR 143/4885AR 188/4885LMNA 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.